Bill to Support the Development of Regenerative Medicine Introduced in Senate

January 29, 2016

Democratic Senator from Wisconsin, Tammy Baldwin, intoduces Bill on Regenerative Medicine

On Tuesday, January 12, 2016, Senator Tammy Baldwin (D – WI) introduced the “Advancing Standards in Regenerative Medicine Act,” a bill supporting the development of regulatory science and the accompanying standards for regenerative medicine and other advancing therapies.

Regenerative medicines include cellular therapies, gene therapies, and tissue products, which “represent a growing field that holds the potential for more targeted medical treatments for chronic and life-threatening diseases.”

In a recent press release, Senator Baldwin claimed, if passed, that the bill “would direct the U.S. Food and Drug Administration (FDA) to facilitate the establishment of a public-private Standards Coordinating Body (SCB) in Regenerative Medicine.” The act would also allow FDA to participate in the development of related standards and to issue guidance on how the Agency could use those standards in the review of applicable products.

The press release stated that, in order “to help foster innovation and truly grow this evolving industry, stakeholders, researchers and the FDA need to come together on best practices, and basic technical and process standards.” Additionally, Baldwin also claimed that “both FDA and innovators will benefit by having standardized measurement processes from which to evaluate products.”

If you are in the process of developing a product that is considered a regenerative medicine or advancing therapy, we can help you achieve a successful interaction with FDA. For more information on our services and how can help you, contact us today.


October 23, 2015

Senate on FDA: Improving the Speed of INDs, PMAs, and NDAs

On October 21, 2015, Senators Joe Donnelly (D – IN) and Cory Gardner (R – CO) announced two new bills – the Rare Device Innovation Act and the FDA Regulatory Efficiency Act – which the pair will be...

December 15, 2015

New Law Provides More Certainty on When Controlled Substances are Officially Approved

President Obama recently signed the Improving Regulatory Transparency for New Medical Therapies Act into law. The law clarifies when controlled substances are officially approved by the FDA,...

October 27, 2015

House Committee Releases Draft Discussion Bill Regarding FDA's Regulations of In Vitro Clinical Testing

On Tuesday, November 17, 2015, the House of Representatives’ Energy & Commerce Committee will hold a hearing entitled, “Examining the Regulation of Diagnostic Tests and Laboratory Operations.” The...